CervoMed Inc. (CRVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.755x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.02 Million) by net assets ($10.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of CervoMed Inc. to measure how much of total assets are equity-financed.
CervoMed Inc. - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CRVO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synergy House Berhad
KLSE:0279
|
0.111x |
|
Skin n Skin Co. Ltd
KQ:159910
|
-0.047x |
|
Medhelp Care AB
ST:MEDHLP
|
0.163x |
|
Investors House
HE:INVEST
|
-0.089x |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.097x |
|
PLB Engineering Bhd
KLSE:7055
|
-0.033x |
|
Petratherm Ltd
AU:PTR
|
-0.044x |
|
Ugint Co Ltd
KQ:195990
|
-0.098x |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2025)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see CRVO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.22 Million | $-23.45 Million | -1.287x | -205.17% |
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more